. 2022 Dec 23;141(12):1379–1388. doi: 10.1182/blood.2022017035

Table 3.

Evidence of CNS activity of antibody-based therapeutics for relapsed/refractory B-ALL

Agent	Mechanism of action	Evidence of CNS activity^∗
Blinatumomab	CD3-CD19 bispecific T-cell engager	Limited: 1 retrospective series⁸⁴
Inotuzumab ozogamicin	CD22 antibody-drug conjugate	None
Tisagenlecleucel	CD19 CAR T cells	Moderate: pooled post hoc analysis of prospective studies and multiple retrospective series⁸⁵^,⁸⁶^,⁸⁷
Brexucabtagene autoleucel	CD19 CAR T cells	Limited: extrapolated from experience with other CAR T-cell therapies

^∗

Please see text and references cited for additional details.